- Home
- FNLC vs CTMX Comparison
FNLC vs CTMX Comparison
Compare FNLC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- CTMX
- Stock Information
- Founded
- FNLC 1864
- CTMX 2008
- Country
- FNLC United States
- CTMX United States
- Employees
- FNLC N/A
- CTMX N/A
- Industry
- FNLC Major Banks
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- CTMX Health Care
- Exchange
- FNLC Nasdaq
- CTMX Nasdaq
- Market Cap
- FNLC 303.4M
- CTMX 349.6M
- IPO Year
- FNLC 1999
- CTMX 2015
- Fundamental
- Price
- FNLC $26.41
- CTMX $1.96
- Analyst Decision
- FNLC
- CTMX Strong Buy
- Analyst Count
- FNLC 0
- CTMX 3
- Target Price
- FNLC N/A
- CTMX $5.67
- AVG Volume (30 Days)
- FNLC 15.5K
- CTMX 2.4M
- Earning Date
- FNLC 10-22-2025
- CTMX 11-06-2025
- Dividend Yield
- FNLC 5.56%
- CTMX N/A
- EPS Growth
- FNLC 13.09
- CTMX 263.20
- EPS
- FNLC 2.68
- CTMX 0.49
- Revenue
- FNLC $85,448,000.00
- CTMX $141,100,000.00
- Revenue This Year
- FNLC N/A
- CTMX N/A
- Revenue Next Year
- FNLC N/A
- CTMX N/A
- P/E Ratio
- FNLC $10.03
- CTMX $3.99
- Revenue Growth
- FNLC 10.86
- CTMX 18.01
- 52 Week Low
- FNLC $22.11
- CTMX $0.40
- 52 Week High
- FNLC $31.05
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- FNLC 46.67
- CTMX 42.56
- Support Level
- FNLC $26.75
- CTMX $2.04
- Resistance Level
- FNLC $27.32
- CTMX $2.16
- Average True Range (ATR)
- FNLC 0.46
- CTMX 0.13
- MACD
- FNLC -0.10
- CTMX -0.01
- Stochastic Oscillator
- FNLC 7.03
- CTMX 15.00
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.